Lantheus Gets FDA Clearance for Prostate Cancer Software

Lantheus Holdings subsidiary Exini Diagnostics has received 510(k) clearance from the FDA for its aPromise image evaluation software for prostate cancer.

The software delivers rapid quantitative assessments of images, “enabling clinicians to make routine use in the clinic of a comprehensive, automated approach to patient evaluation,” North Billerica, Mass.-based Lantheus said.

The automated software provides body segmentation and marking of suspicious cancer lesions in their anatomical context, the company said.